Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Goodwill & Intangibles (2018 - 2025)

Historic Goodwill & Intangibles for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to $20.3 million.

  • Autolus Therapeutics' Goodwill & Intangibles changed N/A to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is N/A changed from last year.
  • Autolus Therapeutics' Goodwill & Intangibles amounted to $20.3 million in Q3 2025.
  • Autolus Therapeutics' 5-year Goodwill & Intangibles high stood at $20.3 million for Q3 2025, and its period low was $8000.0 during Q3 2022.
  • Over the past 4 years, Autolus Therapeutics' median Goodwill & Intangibles value was $112000.0 (recorded in 2021), while the average stood at $5.3 million.
  • In the last 5 years, Autolus Therapeutics' Goodwill & Intangibles crashed by 3691.59% in 2021 and then crashed by 9080.46% in 2022.
  • Quarter analysis of 4 years shows Autolus Therapeutics' Goodwill & Intangibles stood at $65000.0 in 2021, then tumbled by 87.69% to $8000.0 in 2022, then surged by 154562.5% to $12.4 million in 2024, then soared by 63.93% to $20.3 million in 2025.
  • Its last three reported values are $20.3 million in Q3 2025, $12.9 million for Q2 2025, and $12.5 million during Q1 2025.